Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy

The tetraspanin transmembrane protein CD9 plays an important role in inhibiting cell motility in numerous neoplastic cell lines, including lung, gastric, pancreatic, and bladder carcinomas. The prognostic importance of CD9 in the survival of gastric carcinoma patients has not been examined to date,...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2010-09, Vol.206 (9), p.607-610
Main Authors: Soyuer, Serdar, Soyuer, Isın, Unal, Dilek, Ucar, Kadir, Yildiz, Oguz Galip, Orhan, Okan
Format: Article
Language:English
Subjects:
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Adult
Aged
Antigens, CD - biosynthesis
Biomarkers, Tumor - analysis
CD9 expression
Chemotherapy, Adjuvant
Digestive System Surgical Procedures
Disease-Free Survival
Female
Gastric cancer
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Membrane Glycoproteins - biosynthesis
Middle Aged
Neoplasm Staging
Prognosis
Proportional Hazards Models
Radiotherapy
Stomach Neoplasms - metabolism
Stomach Neoplasms - pathology
Stomach Neoplasms - therapy
Tetraspanin-29
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The tetraspanin transmembrane protein CD9 plays an important role in inhibiting cell motility in numerous neoplastic cell lines, including lung, gastric, pancreatic, and bladder carcinomas. The prognostic importance of CD9 in the survival of gastric carcinoma patients has not been examined to date, and in the present study, we attempted to define its prognostic value. The study included 49 (35 men and 14 women) patients with locally advanced (stages II–IV) gastric cancer. The median age was 55 years (range, 22–73 years). Surgery was the initial treatment for all patients, followed by adjuvant chemoradiotherapy. Tissue sections were evaluated immunohistochemically with a monoclonal anti-CD9 antibody. Of the 49 patients with gastric adenocarcinoma, 11 (22.4%) were CD9-positive, and 38 (77.6%) were CD9-negative. A significant prognostic value in disease-free survival and overall survival was observed in T classification and CD9 positivity. In conclusion, CD9 expression in gastric cancer appears to be associated with poor prognosis.
ISSN:0344-0338
1618-0631
DOI:10.1016/j.prp.2010.04.004